source
- Sanofi drops Nurix STAT6 degrader program amid molecule-specific concernsSanofi has halted development of an early‑stage STAT6 degrader program that it licensed from Nurix Therapeutics. The decision was announced after the asset entered Phase 1 trials for type 2 inflamm…
- BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…